Patent · US Active

Dalbavancin compositions for treatment of bacterial infections

US8143212B2 · kind B2 · utility

4Cited by

37References

16Claims

0Family size

Assignee

Vicuron Pharmaceuticals Inc. · US

Inventors

Martin Stogniew · Blue Bell, US
Luigi Colombo · Dallas, US
Romeo Ciabatti · Novate Milanese, IT

Key dates

Filing date	Jun 2, 2009
Grant date	Mar 27, 2012
Priority date	—
Expiry date	Jul 31, 2029

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A0, A1, B1, B2, C0, C1, isoB0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection. Dosing regimens for renal patients are also included.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.